Eli Lilly has recently begun dosing patients in the world’s first trial for treatment designed to attack SARS-CoV-2, the virus that causes COVID-19. This investigational treatment, referred to as LY-CoV555, is the first produced as a result of the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Scientists developed
Drug treatment, remdesivir – an anti-viral medicine that has been used against Ebola, appears to shorten recovery time for people with coronavirus is being made available on the NHS. Health Secretary Matt Hancock said it was probably the biggest step forward in the treatment of coronavirus since the crisis began. UK regulators say there is
Public Health England said the antibody test, developed by Swiss pharmaceutical company Roche, was a “very positive development”, Leading it to be approved in England. The blood test looks for antibodies to see if a person has already had the virus and might now have some immunity. Until now, officials have said such tests are
The new UK trial initiative aims to cut the design phase of clinical studies for potential COVID-19 drugs from around 18 months to a few weeks. The ACCORD-2 collaboration will examine the effectiveness of repurposed medicines, potential new drugs, and currently unlicensed therapies in treating COVID-19 patients. Drug compounds that demonstrate effectiveness and safety in the early clinical trials stage
Researchers at Oxford University are working in what has been herald as an unprecedented vaccine development effort to prevent COVID-19, have begun screening healthy volunteers (aged 18-55) for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in
A new laboratory is to be setup at Cambridge university that aims to conduct 30,000 coronavirus tests a day as the UK government sets a target of 100k tests a day by the end of the month in order to aid tackling the pandemic. The new facility would begin with 1,000 to 2,000 daily tests
Our latest industry analytics report features analysis on the drug safety sector within the life sciences industry. Clinical Professionals Group CEO, Yvette Cleland comments: “The global pharmacovigilance (PV) market size was estimated at $4.87 billion in 2019, according to a Global Market Insights report, by 2024 the market is predicted to exceed US$8 billion .
A duty dodged is like a debt unpaid; it is only deferred, and we must come back and settle the account at last
Our latest industry analytics report features analysis on 2019. Clinical Professionals Group CEO, Yvette Cleland comments: “The UK is now on a course very much focused on leaving the EU. There are a plethora of scenarios being peddled across the industry, often based on emotion as much as fact. Last year however our data shows
NHS England says it is scaling up its capacity for testing people for the infection. Meaning 10,000 tests a day can be done – 8,000 more than the 1,500 being carried out currently. Confirmation of any positive test results are then escalated by helping people take the right action to recover or quickly get treatment.
The pharmaceutical company announced positive top-line results from the randomised Phase III BOSTON study of Xpovio (selinexor). The drug in combination with once-weekly Velcade (bortezomib) and low-dose dexamethasone (SVd) met its primary endpoint of a statistically significant increase in progression-free survival (PFS) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd). The trial saw the